Phase II study of C225 (Erbitux or cetuximab) in combination with cisplatin and definitive radiation in unresectable stage IV squamous cell carcinoma of the head and neck

Trial Profile

Phase II study of C225 (Erbitux or cetuximab) in combination with cisplatin and definitive radiation in unresectable stage IV squamous cell carcinoma of the head and neck

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Mar 2011 Planned end date (Jul 2016) added as reported by ClinicalTrials.gov.
    • 17 May 2008 Preliminary results will be presented at ASCO 2008 according to a ImClone Systems media release.
    • 31 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top